An interventional study of Kerecis fish skin in Fistula-in-ano and Draining Wound, sponsored by Mayo Clinic. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Rectal Fistula with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Rectal Fistula · United States.
Among the 20 studies in Rectal Fistula with a site in United States, this one is the 10th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2025, is one of 8 with no phase, and was the 19th registered.
170 studies on the registry are indexed under Rectal Fistula; 45 are open to participants now.
Browse Rectal Fistula studies →7 of the 20 studies in Rectal Fistula with a site in United States are open now. Recruiting first, the newest first:
ECM Therapeutics, Inc. · Sites in United States
Ages 18+
Signum Surgical USA Inc. · Sites in United States
Ages 18–75
RedDress Ltd. · Sites in United States, Israel
Ages 18+
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+
Aroa Biosurgery Limited · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 26 Rectal Fistula studies recruiting now, 18 (69%) set no upper age limit and 7 (27%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 66 across 116 interventional studies indexed under Rectal Fistula.
Median enrollment 21 across the 15 interventional studies, 79 across the 5 observational. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 20 have an industry lead sponsor. The 10 most frequent:
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
Mayo Clinic has 2 studies filed under Rectal Fistula — fewer than ten, so there is no comparison to draw.
3 of the studies in Rectal Fistula with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04190862Weill Medical College of Cornell UniversityE-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas | 2026-12-30 |
| NCT07021742Signum Surgical USA Inc.BioHealx® Anal Fistula Device Post Market Surveillance Study | 2027-02 |
| NCT07035925ECM Therapeutics, Inc.Study Evaluating the Safety and Efficacy of an ECM Hydrogel for the Treatment of Anorectal Fistulas | 2027-02-24 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies in Rectal Fistula with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine feasibility of Kerecis intact fish skin for healing of fistula-in-ano and associated non-healing draining wounds.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Fistula-in-ano associated with:
To assess shot-term outcomes (rates of healing) using Kerecis intact fish skin to heal cryptoglandular fistula-in-ano and associated chronic non-healing draining wounds.
Device: Kerecis fish skin
To assess shot-term outcomes (rates of healing) using Kerecis intact fish skin to heal cryptoglandular fistula-in-ano and associated chronic non-healing draining wounds.
Fistula healing
Assess healing of the fistula. This will be determined based on physical examination. A healed fistula will be a patient who 6 months after surgery no longer has drainage or evidence of infection. The internal opening should be closed on physical exam. The internal opening should feel closed on digital rectal exam. This will be assessed in each patient to determine the overall rate of healing.
Time frame: From device implant until 6 months after
Plan to share: No
Started Sep 2025 (actual). Primary completion is estimated for Oct 2026, 13 months after the start.
Of 54 non-industry interventional studies with no phase under Rectal Fistula, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 36. This study's planned 13 months is below that.
Counting every sponsor, half of 58 studies reached it within 27 months; a quarter within 11 and three quarters within 38.
Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 8, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.